ATE319817T1 - Gegen inaktivierung resistenter faktor viii - Google Patents

Gegen inaktivierung resistenter faktor viii

Info

Publication number
ATE319817T1
ATE319817T1 AT97927596T AT97927596T ATE319817T1 AT E319817 T1 ATE319817 T1 AT E319817T1 AT 97927596 T AT97927596 T AT 97927596T AT 97927596 T AT97927596 T AT 97927596T AT E319817 T1 ATE319817 T1 AT E319817T1
Authority
AT
Austria
Prior art keywords
acid sequences
sequences
proteins
amino acid
nucleic acid
Prior art date
Application number
AT97927596T
Other languages
German (de)
English (en)
Inventor
Randal J Kaufman
Steven W Pipe
Kagehiro Amano
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Application granted granted Critical
Publication of ATE319817T1 publication Critical patent/ATE319817T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97927596T 1996-04-24 1997-04-24 Gegen inaktivierung resistenter faktor viii ATE319817T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1611796P 1996-04-24 1996-04-24
US1778596P 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
ATE319817T1 true ATE319817T1 (de) 2006-03-15

Family

ID=26688196

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97927596T ATE319817T1 (de) 1996-04-24 1997-04-24 Gegen inaktivierung resistenter faktor viii
AT06004484T ATE502958T1 (de) 1996-04-24 1997-04-24 Gegen inaktivierung resistenter faktor viii

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06004484T ATE502958T1 (de) 1996-04-24 1997-04-24 Gegen inaktivierung resistenter faktor viii

Country Status (10)

Country Link
US (2) US6838437B2 (enExample)
EP (3) EP0910628B1 (enExample)
JP (2) JP3987114B2 (enExample)
AT (2) ATE319817T1 (enExample)
AU (1) AU3202797A (enExample)
CA (1) CA2252896C (enExample)
DE (2) DE69735421T2 (enExample)
DK (1) DK1754718T3 (enExample)
PT (1) PT1754718E (enExample)
WO (1) WO1997040145A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0833848T3 (da) * 1995-06-12 2001-11-05 Sanquin Bloedvoorziening Faktor IX-bindende peptider afledt af faktor VIII og anvendelse heraf som inhibitorer af blodkoagulation
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US20040092442A1 (en) * 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
EP0910628B1 (en) 1996-04-24 2006-03-08 The Regents of The University of Michigan Inactivation resistant factor viii
AU3289599A (en) * 1998-02-13 1999-08-30 Cadus Pharmaceutical Corporation Mekk1 proteins and fragments thereof for use in regulating apoptosis
EP1351986A2 (en) * 2001-01-12 2003-10-15 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
WO2003100053A1 (en) * 2002-05-22 2003-12-04 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hemophilia a
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1502921A1 (en) * 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
CN101098883B (zh) * 2004-12-23 2013-01-23 诺和诺德医疗保健公司 减少含有目的维生素k依赖性蛋白质的组合物中的蛋白质污染物的含量
US20110124565A1 (en) * 2005-04-14 2011-05-26 Hans-Peter Hauser Modified Coagulation Factor VIII With Enhanced Stability and Its Derivatives
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
US20080070251A1 (en) * 2006-06-30 2008-03-20 Kaufman Randal J Method of Producing Factor VIII Proteins by Recombinant Methods
US8754194B2 (en) 2006-12-22 2014-06-17 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
CA2816575C (en) * 2010-11-05 2019-06-11 Baxter Healthcare S.A. A new variant of antihemophilic factor viii having increased specific activity
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
KR20140083036A (ko) 2011-10-18 2014-07-03 체에스엘 베링 게엠베하 인자 ｖｉｉｉ의 생체이용률을 향상시키기 위한 황산화 글리코사미노글리칸의 용도
KR20140083035A (ko) 2011-10-18 2014-07-03 체에스엘 베링 게엠베하 인자 ｖｉｉｉ의 생체이용률을 증가시키기 위한 황산화 글리코사미노글리칸과 하이알루로니다제의 병용 사용
AU2012318292B2 (en) 2011-10-18 2015-08-20 Csl Limited Method for improving the stability of purified Factor VIII after reconstitution
PL2814502T3 (pl) 2012-02-15 2018-02-28 Csl Behring Gmbh Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII
US20150337028A1 (en) * 2012-09-12 2015-11-26 Centre For Bioseparation Technology-Vit Double Mutant Coagulation Factor VIII and Methods Thereof
KR20150088853A (ko) 2012-11-29 2015-08-03 바이엘 헬스케어 엘엘씨 활성화 단백질 c에 대한 인간화 모노클로날 항체 및 그의 용도
EP2925351A4 (en) * 2012-11-29 2016-08-24 Bayer Healthcare Llc MONOCLONAL ANTIBODIES DIRECTED AGAINST ACTIVATED PROTEIN C (APC)
US9914764B2 (en) 2013-03-15 2018-03-13 Bayer Healthcare, Llc Variant factor VIII polypeptides and methods of their production and use
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
EP3164150B1 (en) 2014-07-02 2020-11-04 CSL Behring Lengnau AG Modified von willebrand factor
KR20170125941A (ko) 2015-03-06 2017-11-15 체에스엘 베링 리컴비넌트 퍼실리티 아게 개선된 반감기를 갖는 변형된 폰 빌레브란트 인자
WO2016142289A1 (en) * 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Compounds for improving the half-life of von willebrand factor
EP4089109A3 (en) 2015-05-22 2023-03-01 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
BR112017023785A2 (pt) 2015-05-22 2018-07-17 Csl Behring Recombinant Facility Ag polipeptídeos do fator de von willebrand truncados para tratar hemofilia
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
RU2018128582A (ru) 2016-01-07 2020-02-11 Цсл Беринг Ленгнау Аг Мутированный укороченный фактор фон виллебранда
DK3400238T3 (da) 2016-01-07 2021-07-26 CSL Behring Lengnau AG Muteret von willebrand faktor
SG11201903954WA (en) 2016-11-11 2019-05-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
US11814421B2 (en) 2016-11-11 2023-11-14 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
CA3115535A1 (en) * 2018-10-23 2020-04-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
EP4069269A4 (en) * 2019-12-06 2023-12-27 The Children's Hospital Of Philadelphia COMPOSITIONS AND METHODS FOR MODULATING FACTOR VIII FUNCTION

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214033A (en) 1983-03-31 1993-05-25 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US5045455A (en) 1984-01-12 1991-09-03 Chiron Corporation Factor VIII:C cDNA cloning and expression
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
JPH0788399B2 (ja) 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
WO1987004187A1 (en) 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
AT388079B (de) 1986-04-18 1989-04-25 Helmut Ing Koenig Backofen
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
NZ236094A (en) 1989-11-17 1993-04-28 Chiron Corp Recombinant protein complex having human factor viii:c activity
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
AU6486196A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
WO1997003194A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Lysine 1689 factor viii:c polypeptide analogs
EP0910628B1 (en) 1996-04-24 2006-03-08 The Regents of The University of Michigan Inactivation resistant factor viii

Also Published As

Publication number Publication date
EP1754718A2 (en) 2007-02-21
CA2252896C (en) 2009-03-10
EP1754718B1 (en) 2011-03-23
PT1754718E (pt) 2011-07-13
AU3202797A (en) 1997-11-12
EP0910628A4 (en) 2001-05-02
DK1754718T3 (da) 2011-07-18
JP4250661B2 (ja) 2009-04-08
DE69740154D1 (de) 2011-05-05
US6838437B2 (en) 2005-01-04
ATE502958T1 (de) 2011-04-15
EP0910628B1 (en) 2006-03-08
WO1997040145A1 (en) 1997-10-30
EP1754718A3 (en) 2007-05-16
EP2202242A1 (en) 2010-06-30
JP2000511407A (ja) 2000-09-05
DE69735421D1 (de) 2006-05-04
JP3987114B2 (ja) 2007-10-03
US20020132306A1 (en) 2002-09-19
US20060014683A1 (en) 2006-01-19
JP2007228973A (ja) 2007-09-13
US7459534B2 (en) 2008-12-02
EP0910628A1 (en) 1999-04-28
CA2252896A1 (en) 1997-10-30
DE69735421T2 (de) 2006-10-19

Similar Documents

Publication Publication Date Title
ATE319817T1 (de) Gegen inaktivierung resistenter faktor viii
DK0672138T3 (da) Kimære prokoagulante proteiner
DE69018920D1 (de) Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions-kassetten, transformierte hefen und verfahren zur herstellung dieser proteine.
GEP20033002B (en) Osteoprotegerin Binding Protein and Receptors
DE3854952D1 (de) Mykobakterielle rekombinanten und peptide
EP0731636A4 (en) APOPTOSIS-MODULATING PROTEINS, DNA-ENCODING, AND METHOD FOR THEIR USE
ATE423194T1 (de) Von-willebrand-faktor (vwf) spaltendes protease- polypeptid, für das polypeptid codierende nukleinsäure und verwendung des polypeptids
DE69932599D1 (de) Künstliche chromosomen, die die genetische information für die bildung von rekombinantem virus enthalten
EP0205475A4 (en) RECOMBINANT METHOD FOR THE PRODUCTION OF SERINE PROTEASE INHIBITORS, AND DNA SEQUENCES THEREOF.
SG48173A1 (en) Therapeutic domains of von willebrand factor
ATE148992T1 (de) Zusammensetzungen zur hemmung der bildung von proteinhormon und deren verwendungen
MX9708426A (es) Polipeptido hk2 de variante estable.
ATE211390T1 (de) Überlegende thrombomodulinanaloga zur pharmazeutischen verwendung
ATE291088T1 (de) Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe
SE9602822D0 (sv) New receptor
ATE190630T1 (de) Angiotensin-ii typ-1 rezeptor und dessen herstellung
DE69027967D1 (de) Proteine, die die expression von vertebraten-mhc-klasse-ii-genen regulieren, dafür kodierende dna-sequenzen und pharmazeutische zusammensetzungen
DE60124380D1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
EP0367641A3 (en) Lymphokines, dna sequences encoding these lymphokines and pharmaceutical compositions containing these lymphokines
NO921219D0 (no) Somatostatin reseptor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties